Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H26N2O.ClH.H2O |
Molecular Weight | 328.877 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.CCCN1CCCC[C@H]1C(=O)NC2=C(C)C=CC=C2C
InChI
InChIKey=VSHFRHVKMYGBJL-CKUXDGONSA-N
InChI=1S/C17H26N2O.ClH.H2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3;;/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20);1H;1H2/t15-;;/m0../s1
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C17H26N2O |
Molecular Weight | 274.4011 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Ropivacaine is a member of the amino amide class of local anesthetics and is supplied as the pure S-(-)-enantiomer. It produces effects similar to other local anesthetics via reversible inhibition of sodium ion influx in nerve fibers. Ropivacaine is less lipophilic than bupivacaine and is less likely to penetrate large myelinated motor fibers, resulting in a relatively reduced motor blockade. Thus, ropivacaine has a greater degree of motor-sensory differentiation, which could be useful when the motor blockade is undesirable. The reduced lipophilicity is also associated with decreased potential for central nervous system toxicity and cardiotoxicity. Ropivacaine is indicated for the production of local or regional anesthesia for surgery and for acute pain management.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21712863 | https://www.ncbi.nlm.nih.gov/pubmed/9564403
Curator's Comment: Ropivacaine exerts CNS toxicity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1980 |
2.73 µM [IC50] | ||
Target ID: CHEMBL4306 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9066339 |
80.0 µM [Kd] | ||
Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14665560 |
20.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NAROPIN Approved UseRopivacaine Hydrochloride Injection is indicated for the production of local or regional anesthesia for surgery and for acute pain management. Surgical Anesthesia: epidural block for surgery including cesarean section; major nerve block; local infiltration Acute Pain Management: epidural continuous infusion or intermittent bolus, eg, postoperative or labor; local infiltration Launch Date1996 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.2 mg/L |
40 mg 1 times / day other, intravenous dose: 40 mg route of administration: Intravenous experiment type: OTHER co-administered: |
ROPIVACAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.6 mg/L |
187.5 mg single, epidural dose: 187.5 mg route of administration: Epidural experiment type: SINGLE co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
2.3 mg/L |
300 mg single, epidural dose: 300 mg route of administration: Epidural experiment type: SINGLE co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.4 mg/L |
1493 mg other, epidural dose: 1493 mg route of administration: Epidural experiment type: OTHER co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.8 mg/L |
2075 mg other, epidural dose: 2075 mg route of administration: Epidural experiment type: OTHER co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.1 mg/L |
150 mg single, epidural dose: 150 mg route of administration: Epidural experiment type: SINGLE co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.8 mg × h/L |
40 mg 1 times / day other, intravenous dose: 40 mg route of administration: Intravenous experiment type: OTHER co-administered: |
ROPIVACAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
11.3 mg × h/L |
187.5 mg single, epidural dose: 187.5 mg route of administration: Epidural experiment type: SINGLE co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
13 mg × h/L |
300 mg single, epidural dose: 300 mg route of administration: Epidural experiment type: SINGLE co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
135.5 mg × h/L |
1493 mg other, epidural dose: 1493 mg route of administration: Epidural experiment type: OTHER co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
145 mg × h/L |
2075 mg other, epidural dose: 2075 mg route of administration: Epidural experiment type: OTHER co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.2 mg × h/L |
150 mg single, epidural dose: 150 mg route of administration: Epidural experiment type: SINGLE co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.9 h |
40 mg 1 times / day other, intravenous dose: 40 mg route of administration: Intravenous experiment type: OTHER co-administered: |
ROPIVACAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.1 h |
187.5 mg single, epidural dose: 187.5 mg route of administration: Epidural experiment type: SINGLE co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
6.8 h |
300 mg single, epidural dose: 300 mg route of administration: Epidural experiment type: SINGLE co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5 h |
1493 mg other, epidural dose: 1493 mg route of administration: Epidural experiment type: OTHER co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5.7 h |
2075 mg other, epidural dose: 2075 mg route of administration: Epidural experiment type: OTHER co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5.7 h |
150 mg single, epidural dose: 150 mg route of administration: Epidural experiment type: SINGLE co-administered: |
ROPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
300 mg single, intravascular Overdose Dose: 300 mg Route: intravascular Route: single Dose: 300 mg Sources: |
healthy, 25 years n = 1 Health Status: healthy Age Group: 25 years Sex: F Population Size: 1 Sources: |
Other AEs: Convulsion... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Convulsion | 1 patient | 300 mg single, intravascular Overdose Dose: 300 mg Route: intravascular Route: single Dose: 300 mg Sources: |
healthy, 25 years n = 1 Health Status: healthy Age Group: 25 years Sex: F Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Treatment of acute systemic toxicity after the rapid intravenous injection of ropivacaine and bupivacaine in the conscious dog. | 1991 Oct |
|
Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. | 1997 May |
|
Axillary brachial plexus block with ropivacaine 7.5 mg/ml. A comparative study with bupivacaine 5 mg/ml. | 1999 Sep |
|
Tachycardia and convulsions induced by accidental intravascular ropivacaine injection during sciatic block. | 2002 May |
|
[Convulsions induced by ropivacaine after midhumeral block]. | 2002 Oct |
|
Cardiac arrest after injection of ropivacaine for posterior lumbar plexus blockade. | 2003 Dec |
|
Ropivacaine-induced asystole: "never again" rather than "here we go again". | 2004 Aug |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest. | 2006 Jul |
|
Preexisting subclinical neuropathy as a risk factor for nerve injury after continuous ropivacaine administration through a femoral nerve catheter. | 2006 Nov |
|
The effect of epidural sufentanil in ropivacaine on urinary retention in patients undergoing gastrectomy. | 2006 Sep |
|
Ropivacaine-induced cardiac arrest. | 2007 Jun |
|
Transient unilateral Horner's syndrome after epidural ropivacaine in a dog. | 2009 Jul |
|
Immediate intravenous lipid infusion in the successful resuscitation of ropivacaine-induced cardiac arrest after infraclavicular brachial plexus block. | 2009 May-Jun |
|
Convulsions associated with a low plasma level of local anaesthetics. | 2009 Nov |
|
The addition of fentanyl to 1.5 mg/ml ropivacaine has no advantage for paediatric epidural analgesia. | 2009 Sep |
Sample Use Guides
The dose of any local anesthetic administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient.
For treatment of postoperative pain, the following technique can be recommended: If regional anesthesia was not used intraoperatively, then an initial epidural block with 5-7 mL Naropin is induced via an epidural catheter. Analgesia is maintained with an infusion of Naropin, 2 mg/mL (0.2%). Clinical studies have demonstrated that infusion rates of 6-14 mL (12-28 mg) per hour provide adequate analgesia with nonprogressive motor block. With this technique a significant reduction in the need for opioids was demonstrated. Clinical experience supports the use of Naropin epidural infusions for up to 72 hours.
Route of Administration:
Parenteral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27863837
Dorsal root ganglion neurons were isolated from the SD rats and cultured in vitro. The mRNA of the CaMK II subtype in dorsal root ganglion neurons were detected by real-time PCR. As well as, the dorsal root ganglion neurons were treated with ropivacaine hydrochloride in different concentration (1mM,2mM, 3mM and 4mM) for the same exposure time of 4h, or different exposure time (0h,2h,3h,4h and 6h) at the same concentration(3mM). The changes of the mRNA expression of the CaMK II subtype were observed with real-time PCR. All subtype mRNA of the CaMK II, CaMK IIα, CaMK IIβ, CaMK II δ, CaMK IIγ, can be detected in dorsal root ganglion neurons. With the increased of the concentration and exposure time of the ropivacaine hydrochloride, all the subtype mRNA expression increased. Ropivacaine hydrochloride up-regulate the CaMK IIβ, CaMK IIδ, CaMK IIg mRNA expression with the concentration and exposure time increasing.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:35:36 GMT 2023
by
admin
on
Fri Dec 15 15:35:36 GMT 2023
|
Record UNII |
V910P86109
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1605500
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
V910P86109
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
60803
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
6918111
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
C52198
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
34954
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
236539
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
ALTERNATIVE | |||
|
SUB22590
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
100000090606
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
V910P86109
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
DTXSID80927544
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
132112-35-7
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
CHEMBL1077896
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
SUB04264MIG
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
1298851
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
DBSALT000902
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | |||
|
m9659
Created by
admin on Fri Dec 15 15:35:36 GMT 2023 , Edited by admin on Fri Dec 15 15:35:36 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
USP
|
||
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Capillary electrophoresis
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |